Biodesix reveals adoption of Nodify XL2 for lung nodule management
Category: #healthcare  By Mateen Dalal  Date: 2019-11-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Biodesix reveals adoption of Nodify XL2 for lung nodule management

Risk assessment in lung cancer has become a vital factor for patients with newly diagnosed nodules. Around 3 out of 4 patients are characterized with low to moderate nodules, for which there are no standard procedures to determine the course of action. To counter this, researchers and healthcare firms worldwide are innovating new ways for developing effective lung nodule management techniques.

Biodesix, Inc. is one such diagnostics company that has reportedly announced that Nashville-based leading healthcare service providers Tri-Star Health would be the first hospital system in the U.S. to integrate its recently introduced Nodify XL2™ proteomic classifier for lung nodule management.

Reportedly, around 1.6 million lung nodules are discovered every year in the U.S., but less than 5% turnout to be malignant. However, to avoid invasive diagnostic procedures, Tri-Star Health has implemented routine Nodify XL2 testing; using a blood-based test to help patients who have the risk of malignancy.

Susan Garwood, M.D., Specialist for Pulmonary & Advanced Bronchoscopy Lung Cancer, Centennial Medical Center, said that their hospital focuses on determining the risk of malignancy to make better nodule management decisions.

Currently, patients demand information that influences prompt clinical decision making, whereas the results from Nodify XL2 offer physicians an opportunity to have a personal discussion with each patient regarding the best course of action.

Garwood added that the test results are available within five days, which eliminates the need for invasive bronchoscopy and CT scan. Moreover, Nodify XL2 is easy to integrate with clinical assessment and their clinic’s workflow.

For the record, Nodify XL2 is simple blood tests in which blood sample can be drawn in a doctor’s office and send immediately to Biodesix lab for processing. The test is covered by Medicare and has been clinically accepted in the PANOPTIC study where the result showed a 98% median NPV (negative predictive value) and a potential 40% reduction in unnecessary procedures for minor nodules.

Source Credit - https://www.biodesix.com/press-releases/first-system-wide-integration

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

AstraZeneca’s COVID-19 vaccine manufacturing error clouds trial data
AstraZeneca’s COVID-19 vaccine manufacturing error clouds trial data
By Mateen Dalal

AstraZeneca and Oxford University have recently encountered a manufacturing error of their experimen...

Singapore Airlines raises $500M with the help of 10-year bonds
Singapore Airlines raises $500M with the help of 10-year bonds
By Mateen Dalal

SIA (Singapore Airlines), a flag carrier airline of the country of Singapore, has reportedly raised ...

New TMG 360 Media to optimize time to market for Healthtech companies
New TMG 360 Media to optimize time to market for Healthtech companies
By Mateen Dalal

TMG 360 Media, a novel digital platform created for driving brand awareness, strategic partnerships,...